2022-10-31 Source:
This announcement is made by AIM Vaccine Co., Ltd. (the “Company”, together with its  subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors  of the Company about the latest business updates of the Group.

The board of directors of the Company (the “Board”) is pleased to announce that AIM Kanghuai  Biopharmaceutical (Jiangsu) Co., Ltd. (艾美康淮生物製藥(江蘇)有限公司), a wholly-owned subsidiary of the Company, has recently obtained the clinical trial approval for the EV71-CA16 bivalent HFMD vaccine candidate issued by the Center for Drug Evaluation of National Medical Products Administration.

Hand, foot and mouth disease (HFMD) is a common disease among children below 5 years old in  the People’s Republic of China. Within 1 to 2 days after infection, skin rash can usually be found on the palms, soles and mouth, and blisters may be found on the tongue and gums. Serious HFMD may lead to onychomadesis (separation of fingernails and toenails) within weeks after infection. Viruses causing HFMD are usually transmitted through person-to-person contact, infected patients’  cough and excretion and objects contaminated by the viruses. The most common pathogens of  HFMD are two subtypes of enterovirus, namely the enterovirus 71 (EV71) and Coxsackievirus type  A16 (CA16).

The Group’s EV71-CA16 bivalent HFMD vaccine candidate simultaneously targets the EV71 and CA16 viral strains, which can enhance protection against HFMD.

Meanwhile, investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board AIM Vaccine Co., Ltd.
Mr. Yan ZHOU
Chairman of the Board, Executive Director and  Chief Executive Officer

Hong Kong, October 31, 2022